Abstract
We begin by reviewing the first characterization of fragile X syndrome, which ultimately led to cloning of the FMR1 gene. Discovery of the molecular basis of this disorder, including expansion of a trinucleotide repeat, gave insight not only into fragile X syndrome but also into the premutation syndromes. Features of fragile X syndrome are discussed including the patient phenotype down to the neuronal phenotype. The domain features of the fragile X mental retardation protein FMRP are described, as are the mRNAs bound by FMRP and the role of post-translational modifications as regulators of FMRP function. The relatively new role of FMRP in progenitor cells is reviewed, as is FMRP localization in cells and how FMRP is regulated by glutamatergic signaling in the brain. Understanding how metabotropic glutamate receptors impact FMRP has led to novel therapeutic approaches in treating this disorder.
Keywords: Fragile X, FMRP, RNA binding protein, posttranslational modification, trinucleotide repeat disorder, translation regulation, Fragile X Syndrome, FXS, CGG, FMR1 coding sequence.
Current Protein & Peptide Science
Title:Fragile X Mental Retardation Protein: Past, Present and Future
Volume: 13 Issue: 4
Author(s): Miri Kim and Stephanie Ceman
Affiliation:
Keywords: Fragile X, FMRP, RNA binding protein, posttranslational modification, trinucleotide repeat disorder, translation regulation, Fragile X Syndrome, FXS, CGG, FMR1 coding sequence.
Abstract: We begin by reviewing the first characterization of fragile X syndrome, which ultimately led to cloning of the FMR1 gene. Discovery of the molecular basis of this disorder, including expansion of a trinucleotide repeat, gave insight not only into fragile X syndrome but also into the premutation syndromes. Features of fragile X syndrome are discussed including the patient phenotype down to the neuronal phenotype. The domain features of the fragile X mental retardation protein FMRP are described, as are the mRNAs bound by FMRP and the role of post-translational modifications as regulators of FMRP function. The relatively new role of FMRP in progenitor cells is reviewed, as is FMRP localization in cells and how FMRP is regulated by glutamatergic signaling in the brain. Understanding how metabotropic glutamate receptors impact FMRP has led to novel therapeutic approaches in treating this disorder.
Export Options
About this article
Cite this article as:
Kim Miri and Ceman Stephanie, Fragile X Mental Retardation Protein: Past, Present and Future, Current Protein & Peptide Science 2012; 13 (4) . https://dx.doi.org/10.2174/138920312801619420
DOI https://dx.doi.org/10.2174/138920312801619420 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Intrinsically Disordered Domains, Amyloids and Protein Liquid Phases: Evolving Concepts and Open Questions
Protein & Peptide Letters Preventing the Spread of Alzheimer’s Disease Neuropathology: A Role for Calcilytics?
Current Pharmaceutical Biotechnology The Role of Phosphorylation in Synucleinopathies: Focus on Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Drug Delivery Technologies and Stem Cells for Tissue Repair and Regeneration
Current Pharmaceutical Biotechnology Cross-Interplay between Osmolytes and mTOR in Alzheimer's Disease Pathogenesis
Current Pharmaceutical Design PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
Current Pharmaceutical Design Homology Modeling of Adenosine A2A Receptor and Molecular Docking for Exploration of Appropriate Potent Antagonists for Treatment of Parkinsons Disease
Current Aging Science In Silico Studies in Drug Research Against Neurodegenerative Diseases
Current Neuropharmacology Protein Conformational Diseases: From Mechanisms to Drug Designs
Current Drug Discovery Technologies The Role of 5-Hydroxymethylcytosine in Aging and Alzheimer’s Disease: Current Status and Prospects for Future Studies
Current Alzheimer Research QSAR Applications During Last Decade on Inhibitors of Acetylcholinesterase in Alzheimer’s Disease
Mini-Reviews in Medicinal Chemistry Meet Our Editorial Board Member
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Molecular Pharmacology of the Glycine Receptor Chloride Channel
Current Pharmaceutical Design The Glial Sodium-Calcium Exchanger: A New Target for Nitric Oxide- Mediated Cellular Toxicity
Current Protein & Peptide Science Ischemic Neuronal Damage
Current Pharmaceutical Design Absorption, Pharmacokinetics and Disposition Properties of Solid Lipid Nanoparticles (SLNs)
Current Drug Metabolism Nanotechnology for Alzheimer Disease
Current Alzheimer Research Apo-E4 Allele in Conjunction with Aβ42 and Tau in CSF: Biomarker for Alzheimers Disease
Current Alzheimer Research Editorial (Thematic Issue: Targeting Phosphodiesterases (PDEs) for Treatment of CNS Diseases)
Current Pharmaceutical Design Half a Century of l-DOPA
Current Topics in Medicinal Chemistry